Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 02

114P - Risk factors for oesophageal fistula: A life-threatening complication of treatment for oesophageal cancer

Date

03 Dec 2022

Session

Poster viewing 02

Topics

Tumour Site

Oesophageal Cancer

Presenters

Reo Omori

Citation

Annals of Oncology (2022) 33 (suppl_9): S1454-S1484. 10.1016/annonc/annonc1123

Authors

R. Omori, K. Akiyoshi, Y. Nishibori, Y. NAKATANI, Y. Akaishi, A. Tanaka, S. Tokunaga, H. Daga

Author affiliations

  • Department Of Clinical Oncology, Osaka City General Hospital, 5340021 - Osaka/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 114P

Background

Oesophageal fistula is a life-threatening complication that may occur during oesophageal squamous cell carcinoma treatment. Clinical evidence of established risk factors for the development of fistula is limited. This study investigated the risk factors based on clinical data.

Methods

We retrospectively reviewed clinical data of patients with locally advanced (T4) oesophageal cancer who received chemoradiotherapy or chemotherapy alone in our institute between April 2018 and May 2022. Patients were excluded if they had a fistula before treatment started. T-test, Fisher’s exact test, and logistic regression analysis were used to analyse the data.

Results

Out of 42 patients studied, 19 developed fistula. All patients received chemotherapy. In the fistula group, 11 patients received definitive concurrent radiotherapy, one received palliative radiotherapy, and seven did not receive radiotherapy. Low body mass index (BMI) was the only significant risk factor associated with fistula formation (p=0.042). There was no significant association between oesophageal stricture at baseline, type of radiotherapies, ages, performance status, serum albumin, C-reactive protein, and neutrophil- lymphocyte ratio with fistula formation. The overall survival (OS) in the fistula group was significantly shorter than in the non-fistula group (275 days vs. 447 days, P=0.014). The median survival time from the development of the fistula was 58 days.

Conclusions

In this trial, low BMI at baseline independently increased the risk of oesophageal fistula occurring after oesophageal cancer treatment. It was also identified that oesophageal fistula is associated with poor prognosis. Further prospective studies are needed to establish other risk factors to avoid this unfavourable complication.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.